Why the study?
Iron deficiency is an important therapeutic target in HFrEF, with IV iron showing favorable effects across trials, but defining iron replete status remains a key clinical focus.
Does intravenous iron supplementation improve clinical outcomes and functional status in patients with HFrEF and iron deficiency?
Does intravenous iron supplementation improve clinical outcomes and functional status in patients with HFrEF and iron deficiency?
Answers are grounded in this paper and cite their sources.
The neutral results of the HEART FID trial may be attributed to the use of serum ferritin to define iron deficiency and a stringent maintenance dosing protocol that resulted in under-dosing compared to previous trials.
Iron deficiency is an important therapeutic target in patients with heart failure and reduced ejection fraction (HFrEF). Over the past two decades, several trials of intravenous (IV) iron supplementation in HFrEF have shown favorable effects on symptoms, functional status, and heart failure (HF) hospitalizations...
No takes yet. Share an insight, caveat, or question.
Talha et al. (2023) conducted an editorial in Heart failure with reduced ejection fraction and iron deficiency (n=3,065). Ferric carboxymaltose vs. Placebo was evaluated on Hierarchical composite of 12-months all-cause mortality and heart failure hospitalizations, and change in 6-minute walk test from baseline to 6 months (Win ratio 1.10, 95% CI 0.99-1.23, p=0.019).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: